Page 1 of 108
WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY EXAM
QUESTIONS AND CORRECT VERIFIED SOLUTIONS LATEST
UPDATE THIS YEAR – JUST RELEASED
WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY EXAM
Exam Coverage
Principles of psychopharmacology, pharmacokinetics, pharmacodynamics, and receptor
activity.
Antidepressant medications, therapeutic effects, adverse effects, and monitoring.
Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake
inhibitors.
Tricyclic antidepressants, monoamine oxidase inhibitors, and atypical antidepressants.
Antipsychotic medications, dopamine pathways, therapeutic monitoring, and adverse
effects.
Mood stabilizers, lithium therapy, anticonvulsants, and medication safety.
Anxiolytics, sedative-hypnotics, stimulants, and medications used for sleep disorders.
Medication interactions, contraindications, toxicity, withdrawal, and discontinuation
considerations.
Pharmacologic management of major depressive disorder, bipolar disorder,
schizophrenia, anxiety, and related conditions.
Patient education, adherence, laboratory monitoring, safety assessment, and evidence-
based psychiatric medication management.
Questions
1. Which pharmacokinetic process describes movement of a medication from the
administration site into systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Elimination
, Page 2 of 108
Answer: B
Rationale: Absorption is the process by which a medication enters the systemic circulation from
its administration site.
2. Which pharmacokinetic process primarily describes chemical alteration of a medication
within the body?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: C
Rationale: Metabolism chemically transforms medications, often through hepatic enzyme
systems, into metabolites that may be active or inactive.
3. What does the term half-life describe when discussing a psychotropic medication?
A. Time required for half of the administered drug to be absorbed
B. Time required for the medication to reach peak concentration
C. Time required for half of the drug's amount in the body to be eliminated
D. Time required for the medication to produce its first therapeutic effect
Answer: C
Rationale: Half-life is the time required for the plasma concentration or amount of medication
in the body to decrease by approximately 50%.
, Page 3 of 108
4. Which pharmacodynamic concept describes the interaction between a medication and its
target receptor?
A. Receptor binding
B. Renal clearance
C. Hepatic filtration
D. Gastrointestinal absorption
Answer: A
Rationale: Pharmacodynamics concerns what a drug does to the body, including receptor
binding and downstream physiological effects.
5. A medication that binds to a receptor and produces a biological response is best described
as what?
A. Antagonist
B. Agonist
C. Inhibitor
D. Inducer
Answer: B
Rationale: An agonist binds to a receptor and activates it to produce a physiological response.
6. Which medication characteristic generally increases the potential for drug accumulation
with repeated dosing?
, Page 4 of 108
A. Very short half-life
B. Rapid elimination
C. Long half-life
D. Minimal systemic absorption
Answer: C
Rationale: Drugs with long half-lives remain in the body longer and may accumulate when
administered repeatedly.
7. Why can steady-state concentrations take several days to develop after beginning certain
psychotropic medications?
A. Drug elimination occurs instantly
B. Repeated dosing allows medication concentrations to gradually approach equilibrium
C. Receptors immediately eliminate excess medication
D. Absorption prevents accumulation
Answer: B
Rationale: Steady state is approached over multiple half-lives as drug input and elimination
reach a relatively stable relationship.
8. Which patient characteristic can significantly alter psychotropic medication
pharmacokinetics?
A. Eye color
B. Hair length
WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY EXAM
QUESTIONS AND CORRECT VERIFIED SOLUTIONS LATEST
UPDATE THIS YEAR – JUST RELEASED
WILKES NSG 552 EXAM 1 PSYCHOPHARMACOLOGY EXAM
Exam Coverage
Principles of psychopharmacology, pharmacokinetics, pharmacodynamics, and receptor
activity.
Antidepressant medications, therapeutic effects, adverse effects, and monitoring.
Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake
inhibitors.
Tricyclic antidepressants, monoamine oxidase inhibitors, and atypical antidepressants.
Antipsychotic medications, dopamine pathways, therapeutic monitoring, and adverse
effects.
Mood stabilizers, lithium therapy, anticonvulsants, and medication safety.
Anxiolytics, sedative-hypnotics, stimulants, and medications used for sleep disorders.
Medication interactions, contraindications, toxicity, withdrawal, and discontinuation
considerations.
Pharmacologic management of major depressive disorder, bipolar disorder,
schizophrenia, anxiety, and related conditions.
Patient education, adherence, laboratory monitoring, safety assessment, and evidence-
based psychiatric medication management.
Questions
1. Which pharmacokinetic process describes movement of a medication from the
administration site into systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Elimination
, Page 2 of 108
Answer: B
Rationale: Absorption is the process by which a medication enters the systemic circulation from
its administration site.
2. Which pharmacokinetic process primarily describes chemical alteration of a medication
within the body?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: C
Rationale: Metabolism chemically transforms medications, often through hepatic enzyme
systems, into metabolites that may be active or inactive.
3. What does the term half-life describe when discussing a psychotropic medication?
A. Time required for half of the administered drug to be absorbed
B. Time required for the medication to reach peak concentration
C. Time required for half of the drug's amount in the body to be eliminated
D. Time required for the medication to produce its first therapeutic effect
Answer: C
Rationale: Half-life is the time required for the plasma concentration or amount of medication
in the body to decrease by approximately 50%.
, Page 3 of 108
4. Which pharmacodynamic concept describes the interaction between a medication and its
target receptor?
A. Receptor binding
B. Renal clearance
C. Hepatic filtration
D. Gastrointestinal absorption
Answer: A
Rationale: Pharmacodynamics concerns what a drug does to the body, including receptor
binding and downstream physiological effects.
5. A medication that binds to a receptor and produces a biological response is best described
as what?
A. Antagonist
B. Agonist
C. Inhibitor
D. Inducer
Answer: B
Rationale: An agonist binds to a receptor and activates it to produce a physiological response.
6. Which medication characteristic generally increases the potential for drug accumulation
with repeated dosing?
, Page 4 of 108
A. Very short half-life
B. Rapid elimination
C. Long half-life
D. Minimal systemic absorption
Answer: C
Rationale: Drugs with long half-lives remain in the body longer and may accumulate when
administered repeatedly.
7. Why can steady-state concentrations take several days to develop after beginning certain
psychotropic medications?
A. Drug elimination occurs instantly
B. Repeated dosing allows medication concentrations to gradually approach equilibrium
C. Receptors immediately eliminate excess medication
D. Absorption prevents accumulation
Answer: B
Rationale: Steady state is approached over multiple half-lives as drug input and elimination
reach a relatively stable relationship.
8. Which patient characteristic can significantly alter psychotropic medication
pharmacokinetics?
A. Eye color
B. Hair length
